Skip to content

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents

Depression in Adolescence

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or GLAD-PC guided prescribing (control intervention).

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    12 to 17

Critères de participation

Inclusion Criteria:

* Age 12-17
* Depression as the primary concern, confirmed by the treating physician
* QIDS-A17 score greater than or equal to 11 indicating moderate-to-severe symptoms
* Intention to start a new SSRI
* English fluency

Exclusion Criteria:

* Co-occurring psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
* A score of 2 or 3 on suicide item 13 of the QIDS-A17
* High-risk alcohol or substance use (excluding cannabis and tobacco) as indicated by a score of monthly or more on the S2BI
* History of non-response to 3 or more SSRI medications as confirmed by the treating physician
* Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
* History of liver or hematopoietic cell transplant
* History of CYP2B6, CYP2C19, or CYP2D6 testing

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Backup Contact

Chad Bousman

Primary Contact

Laina McAusland, MSc

[email protected]
Backup Contact

Amanda Newton

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: NCT05965401